Skip to main content
NASDAQ:MDVL

MedAvail Competitors

$11.40
+0.54 (+4.97 %)
(As of 05/14/2021 01:20 PM ET)
Add
Compare
Today's Range
$11.06
$11.40
50-Day Range
$11.50
$15.03
52-Week Range
$9.00
$46.20
Volume299 shs
Average Volume88,184 shs
Market Capitalization$364.18 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2

Competitors

MedAvail (NASDAQ:MDVL) Vs. CMPS, PMVP, INVA, ENDP, ARQT, and IMGN

Should you be buying MDVL stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to MedAvail, including COMPASS Pathways (CMPS), PMV Pharmaceuticals (PMVP), Innoviva (INVA), Endo International (ENDP), Arcutis Biotherapeutics (ARQT), and ImmunoGen (IMGN).

COMPASS Pathways (NASDAQ:CMPS) and MedAvail (NASDAQ:MDVL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Insider and Institutional Ownership

15.8% of COMPASS Pathways shares are owned by institutional investors. Comparatively, 40.2% of MedAvail shares are owned by institutional investors. 45.3% of MedAvail shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares COMPASS Pathways and MedAvail's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
COMPASS PathwaysN/AN/AN/A
MedAvail-245.38%-168.39%-104.11%

Analyst Ratings

This is a summary of current ratings for COMPASS Pathways and MedAvail, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
COMPASS Pathways00703.00
MedAvail00203.00

COMPASS Pathways presently has a consensus target price of $70.80, indicating a potential upside of 108.79%. MedAvail has a consensus target price of $20.00, indicating a potential upside of 78.41%. Given COMPASS Pathways' higher possible upside, equities research analysts clearly believe COMPASS Pathways is more favorable than MedAvail.

Valuation and Earnings

This table compares COMPASS Pathways and MedAvail's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
COMPASS PathwaysN/AN/A$-19,610,000.00N/AN/A
MedAvail$1.03 million353.58$-4,260,000.00($5.52)-2.07

MedAvail has higher revenue and earnings than COMPASS Pathways.

Summary

COMPASS Pathways beats MedAvail on 5 of the 9 factors compared between the two stocks.

PMV Pharmaceuticals (NASDAQ:PMVP) and MedAvail (NASDAQ:MDVL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Valuation and Earnings

This table compares PMV Pharmaceuticals and MedAvail's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PMV PharmaceuticalsN/AN/AN/AN/AN/A
MedAvail$1.03 million353.58$-4,260,000.00($5.52)-2.07

PMV Pharmaceuticals has higher earnings, but lower revenue than MedAvail.

Profitability

This table compares PMV Pharmaceuticals and MedAvail's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PMV PharmaceuticalsN/AN/AN/A
MedAvail-245.38%-168.39%-104.11%

Analyst Ratings

This is a summary of current ratings and recommmendations for PMV Pharmaceuticals and MedAvail, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PMV Pharmaceuticals01302.75
MedAvail00203.00

PMV Pharmaceuticals presently has a consensus target price of $38.00, suggesting a potential upside of 18.79%. MedAvail has a consensus target price of $20.00, suggesting a potential upside of 78.41%. Given MedAvail's stronger consensus rating and higher probable upside, analysts plainly believe MedAvail is more favorable than PMV Pharmaceuticals.

Insider & Institutional Ownership

69.7% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 40.2% of MedAvail shares are held by institutional investors. 45.3% of MedAvail shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

PMV Pharmaceuticals beats MedAvail on 5 of the 9 factors compared between the two stocks.

Innoviva (NASDAQ:INVA) and MedAvail (NASDAQ:MDVL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Innoviva and MedAvail, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Innoviva10001.00
MedAvail00203.00

Innoviva currently has a consensus price target of $10.00, indicating a potential downside of 21.69%. MedAvail has a consensus price target of $20.00, indicating a potential upside of 78.41%. Given MedAvail's stronger consensus rating and higher possible upside, analysts clearly believe MedAvail is more favorable than Innoviva.

Risk & Volatility

Innoviva has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, MedAvail has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Institutional & Insider Ownership

71.5% of Innoviva shares are held by institutional investors. Comparatively, 40.2% of MedAvail shares are held by institutional investors. 0.3% of Innoviva shares are held by insiders. Comparatively, 45.3% of MedAvail shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Innoviva and MedAvail's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innoviva$261.02 million4.96$157.29 million$1.438.94
MedAvail$1.03 million353.58$-4,260,000.00($5.52)-2.07

Innoviva has higher revenue and earnings than MedAvail. MedAvail is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Innoviva and MedAvail's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Innoviva67.16%53.99%28.92%
MedAvail-245.38%-168.39%-104.11%

Summary

Innoviva beats MedAvail on 8 of the 14 factors compared between the two stocks.

Endo International (NASDAQ:ENDP) and MedAvail (NASDAQ:MDVL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.

Risk and Volatility

Endo International has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, MedAvail has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

Profitability

This table compares Endo International and MedAvail's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Endo International-5.30%-85.80%7.19%
MedAvail-245.38%-168.39%-104.11%

Earnings & Valuation

This table compares Endo International and MedAvail's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Endo International$2.91 billion0.44$-422,640,000.00$2.382.33
MedAvail$1.03 million353.58$-4,260,000.00($5.52)-2.07

MedAvail has lower revenue, but higher earnings than Endo International. MedAvail is trading at a lower price-to-earnings ratio than Endo International, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

80.0% of Endo International shares are held by institutional investors. Comparatively, 40.2% of MedAvail shares are held by institutional investors. 1.5% of Endo International shares are held by insiders. Comparatively, 45.3% of MedAvail shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Endo International and MedAvail, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Endo International23202.00
MedAvail00203.00

Endo International currently has a consensus target price of $7.6667, suggesting a potential upside of 38.89%. MedAvail has a consensus target price of $20.00, suggesting a potential upside of 78.41%. Given MedAvail's stronger consensus rating and higher possible upside, analysts plainly believe MedAvail is more favorable than Endo International.

Summary

Endo International beats MedAvail on 7 of the 13 factors compared between the two stocks.

MedAvail (NASDAQ:MDVL) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for MedAvail and Arcutis Biotherapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MedAvail00203.00
Arcutis Biotherapeutics00403.00

MedAvail currently has a consensus price target of $20.00, suggesting a potential upside of 78.41%. Arcutis Biotherapeutics has a consensus price target of $54.6667, suggesting a potential upside of 113.96%. Given Arcutis Biotherapeutics' higher probable upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than MedAvail.

Profitability

This table compares MedAvail and Arcutis Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MedAvail-245.38%-168.39%-104.11%
Arcutis BiotherapeuticsN/A-81.74%-57.72%

Insider and Institutional Ownership

40.2% of MedAvail shares are owned by institutional investors. Comparatively, 79.6% of Arcutis Biotherapeutics shares are owned by institutional investors. 45.3% of MedAvail shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares MedAvail and Arcutis Biotherapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MedAvail$1.03 million353.58$-4,260,000.00($5.52)-2.07
Arcutis BiotherapeuticsN/AN/A$-42,000,000.00($22.78)-1.12

MedAvail has higher revenue and earnings than Arcutis Biotherapeutics. MedAvail is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Arcutis Biotherapeutics beats MedAvail on 7 of the 11 factors compared between the two stocks.

MedAvail (NASDAQ:MDVL) and ImmunoGen (NASDAQ:IMGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Profitability

This table compares MedAvail and ImmunoGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MedAvail-245.38%-168.39%-104.11%
ImmunoGen-77.65%N/A-26.98%

Analyst Ratings

This is a summary of recent ratings and recommmendations for MedAvail and ImmunoGen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MedAvail00203.00
ImmunoGen03402.57

MedAvail currently has a consensus target price of $20.00, indicating a potential upside of 78.41%. ImmunoGen has a consensus target price of $10.10, indicating a potential upside of 50.52%. Given MedAvail's stronger consensus rating and higher probable upside, equities research analysts clearly believe MedAvail is more favorable than ImmunoGen.

Valuation & Earnings

This table compares MedAvail and ImmunoGen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MedAvail$1.03 million353.58$-4,260,000.00($5.52)-2.07
ImmunoGen$82.27 million16.26$-104,130,000.00($0.70)-9.56

MedAvail has higher earnings, but lower revenue than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than MedAvail, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

MedAvail has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, ImmunoGen has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.

Institutional & Insider Ownership

40.2% of MedAvail shares are owned by institutional investors. Comparatively, 73.0% of ImmunoGen shares are owned by institutional investors. 45.3% of MedAvail shares are owned by company insiders. Comparatively, 3.8% of ImmunoGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

ImmunoGen beats MedAvail on 8 of the 14 factors compared between the two stocks.


MedAvail Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$33.80+3.0%$1.31 billionN/A0.00Earnings Announcement
Analyst Report
Gap Up
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$31.99+9.3%$1.30 billionN/A0.00Gap Up
Innoviva logo
INVA
Innoviva
1.1$12.78+0.2%$1.29 billion$261.02 million6.52
Endo International logo
ENDP
Endo International
1.5$5.54+0.2%$1.29 billion$2.91 billion-8.15Analyst Revision
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$25.44+0.4%$1.28 billionN/A-2.76
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.69+4.3%$1.28 billion$82.27 million-16.32Earnings Announcement
Analyst Revision
Gap Up
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$30.45+4.8%$1.27 billion$230,000.00-14.16Gap Up
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$29.24+0.3%$1.27 billion$6.20 million-12.82Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Zymeworks logo
ZYME
Zymeworks
1.6$28.57+6.8%$1.23 billion$29.54 million-7.58Analyst Report
Gap Up
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.5$35.88+7.0%$1.23 billionN/A-19.93Earnings Announcement
Analyst Revision
Gap Up
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$18.91+1.0%$1.22 billion$73.41 million-4.00Analyst Report
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.81+2.7%$1.17 billion$59.70 million-198.10
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$32.16+3.0%$1.15 billionN/A0.00Earnings Announcement
News Coverage
Gap Down
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$17.98+5.1%$1.14 billion$175.34 million-10.58Gap Down
Omeros logo
OMER
Omeros
1.4$18.52+1.0%$1.14 billion$111.81 million-7.78Earnings Announcement
Analyst Downgrade
Analyst Revision
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.08+0.7%$1.14 billion$4.23 million-8.42
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$20.92+1.5%$1.11 billion$4.23 million-15.50
Shattuck Labs logo
STTK
Shattuck Labs
1.5$25.59+2.2%$1.10 billionN/A0.00Earnings Announcement
Insider Selling
Gap Up
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.6$27.31+1.1%$1.09 billion$800.40 million25.76Analyst Report
News Coverage
Keros Therapeutics logo
KROS
Keros Therapeutics
1.5$48.34+4.2%$1.08 billionN/A0.00Analyst Downgrade
Analyst Revision
Gap Down
Zogenix logo
ZGNX
Zogenix
2.0$19.15+0.5%$1.07 billion$3.65 million-2.01Insider Buying
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$33.87+0.4%$1.06 billionN/A-2.42Analyst Upgrade
Insider Selling
Analyst Revision
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$22.69+6.7%$1.06 billionN/A-7.46
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
2.0$28.35+3.2%$1.05 billion$57.05 million0.00Earnings Announcement
Analyst Revision
News Coverage
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$18.50+0.5%$1.02 billion$227.19 million51.39Analyst Report
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$51.69+2.7%$1.02 billion$122.47 million-28.40
MannKind logo
MNKD
MannKind
1.4$4.31+6.5%$1.00 billion$63.04 million-20.52Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$14.76+2.8%$990.88 million$42.12 million-10.93Earnings Announcement
Analyst Revision
News Coverage
Humanigen logo
HGEN
Humanigen
1.7$17.68+5.4%$981.33 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Up
OLMA
Olema Pharmaceuticals
1.6$24.62+2.2%$966.89 millionN/A0.00Earnings Announcement
Lockup Expiration
Analyst Revision
News Coverage
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$28.23+1.8%$965.56 millionN/A-13.01Earnings Announcement
News Coverage
Radius Health logo
RDUS
Radius Health
1.1$20.58+2.1%$951.95 million$173.32 million-8.43Earnings Announcement
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$14.05+1.6%$943.65 millionN/A-5.93
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$19.87+1.6%$931.74 million$322.36 million141.93Insider Selling
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$20.39+5.8%$919.97 millionN/A-7.52Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Up
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$28.73+5.5%$917.13 millionN/A-26.60Analyst Revision
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$25.14+3.6%$889.51 millionN/A0.00News Coverage
Gap Up
Epizyme logo
EPZM
Epizyme
1.9$9.12+4.9%$884.13 million$23.80 million-4.09Analyst Report
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.8$18.55+2.4%$873.55 million$1.52 million-9.87Earnings Announcement
Analyst Upgrade
Analyst Revision
Affimed logo
AFMD
Affimed
1.6$9.10+2.6%$870.82 million$23.96 million-15.42News Coverage
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$8.55+1.2%$870.63 million$120,000.00-3.17Earnings Announcement
Unusual Options Activity
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$21.59+4.2%$870.51 millionN/A-7.44Insider Selling
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.4$17.69+4.0%$869.48 millionN/A0.00News Coverage
Gap Up
Prothena logo
PRTA
Prothena
2.1$22.94+5.7%$865.33 million$810,000.00-8.96Earnings Announcement
Analyst Report
Analyst Revision
Merus logo
MRUS
Merus
1.8$22.07+0.3%$843.70 million$31.13 million-7.19Analyst Revision
News Coverage
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$7.69+4.7%$839.93 million$35.22 million-5.61Analyst Downgrade
Nkarta logo
NKTX
Nkarta
1.8$27.89+14.2%$786.93 millionN/A0.00Earnings Announcement
News Coverage
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.6$22.37+2.8%$766.29 million$296.70 million45.65Insider Selling
Annexon logo
ANNX
Annexon
1.9$20.58+4.2%$754.09 millionN/A0.00
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.4$30.60+0.7%$748.81 millionN/A-9.08Earnings Announcement
Analyst Report
Analyst Revision
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.